MicroRNAs (miRNAs) are involved in gene regulation of several physiological processes. Alterations in the concentrations of miRNAs may result in cancer and autoimmune diseases. In cells of the immune system, miRNA expression is regulated by several cytokines and this expression is related to the inflammatory process. In the present work we evaluated miR-155 and miR-146a levels in peripheral blood mononuclear cells (PBMC) from patients with type 2 diabetes (T2D).We analysed the expression of miRNAs in PBMC from T2D patients (n=20) and control subjects (n=20) using real-time PCR. The quantity of IL-1β and IL-6 in culture supernatants was measured by ELISA.The basal expression of miR-155 and miR-146a in patients with T2D was decreased compared to control subjects and associated with age, gender and metabolic control but not with the therapeutic treatment used. We found significant correlations between the basal expression of miR-155 and miR-146a with HbA1c, Glucose and BMI, as well as of miR-155 expression stimulated by LPS with the values of TG, HbA1c, Glucose and BMI. Additionally, we detected an altered distribution of miR-155 and miR-146a expression related with HbA1c, glucose and BMI using the analysis of a three dimensional association of variables in the group of T2D patients.Downregulated levels of miR-155 could play an important role in the pathogenesis of T2D due to their relationship with metabolic control.
Tuberculosis is one of the most important infectious diseases worldwide. The susceptibility to this disease depends to a great extent on the innate immune response against mycobacteria. Host defense peptides (HDP) are one of the first barriers to counteract infection. Cathelicidin (LL-37) is an HDP that has many immunomodulatory effects besides its weak antimicrobial activity. Despite advances in the study of the innate immune response in tuberculosis, the immunological role of LL-37 during M. tuberculosis infection has not been clarified. Monocyte-derived macrophages were infected with M. tuberculosis strain H37Rv and then treated with 1, 5, or 15 g/ml of exogenous LL-37 for 4, 8, and 24 h. Exogenous LL-37 decreased tumor necrosis factor alpha (TNF-␣) and interleukin-17 (IL-17) while inducing anti-inflammatory IL-10 and transforming growth factor  (TGF-) production. Interestingly, the decreased production of anti-inflammatory cytokines did not reduce antimycobacterial activity. These results are consistent with the concept that LL-37 can modulate the expression of cytokines during mycobacterial infection and this activity was independent of the P2X7 receptor. Thus, LL-37 modulates the response of macrophages during infection, controlling the expression of proinflammatory and anti-inflammatory cytokines.T uberculosis (TB), caused by Mycobacterium tuberculosis, is the single deadliest communicable disease. In 2013, an estimated 9.0 million people developed TB and 1.5 million died from the disease (1).The main cells involved in the control of tuberculosis are macrophages, and together with epithelial cells, they are the first antiinfective immunological barriers encountered, with a primary task to initiate pathogen clearance. In the progress of cellular immunity against M. tuberculosis, macrophages can also function as antigen-presenting cells, in which the antigens of M. tuberculosis are degraded into immunogenic polypeptides and presented on T lymphocytes by the major histocompatibility complex to trigger adaptive immunity. However, M. tuberculosis has developed a wide assortment of strategies to counteract the bactericidal activities of these cells, enabling it to successfully establish a niche for long-term survival within macrophages. This M. tuberculosis replication causes mild inflammation, which promotes cell-mediated immunity that often leads to M. tuberculosis retention through granuloma (tubercle) formation (2). When infection becomes reactivated at a low rate, the granuloma suffers caseous necrosis, and this results in lung cavitation and pulmonary disease, inducing a prominent inflammation (3). Several molecules of the immune system are involved throughout this process, including host defense peptides (HDP) such as cathelicidin and defensins (4-6).LL-37 is the unique member of cathelicidin family in humans; this multifunctional immunomodulatory HDP is produced mainly by phagocytic leukocytes and epithelial cells as well as being normally found at concentrations varying from 2 to 5 g/ml in several fl...
BACKGROUND Type 2 diabetes (T2D) is a risk factor for the development of tuberculosis (TB), although the associated mechanisms are not known.OBJECTIVES To study the association between T2D and the basal phenotype of macrophages, and their immune response to Mycobacterium tuberculosis (Mtb) infection.METHODS We evaluated the influence of T2D on the response of monocyte-derived macrophages (MDM) to Mtb in patients with T2D (n = 10) compared to healthy subjects (n = 9), before and after infection with Mtb clinical isolates bearing different degrees of virulence. The levels of cell surface markers for activation secreted cytokines and chemokines, bacterial association, and intracellular bacterial growth were evaluated.FINDINGS The expression levels of HLA-DR, CD80, and CD86 were low while those of of PD-L1 were high in uninfected MDMs derived from patients with diabetes; as a result of Mtb infection, changes were only observed in the expression levels of PD-L1. The levels of cytokines (e.g., IL-6, IL-1β, IL-10, and IL-12) and chemokines (e.g., MCP-1, MIG, and RANTES) are perturbed in MDMs derived from patients with diabetes, both before infection and in response to Mtb infection. In response to the more virulent Mtb strains, the levels of association and bacterial clearance were diminished in MDMs derived from patients with diabetes.CONCLUSIONS T2D affects the basal activation state of the macrophages and its capacity to respond and control Mtb infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.